Duzopharm® (Dusopharm®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceNaphthyrofurylNaphthyrofuryl
Similar drugsTo uncover
  • Duzopharm®
    pills inwards 
    ESCO PHARMA, LLC    
    • Dosage form: & nbspfilm coated tablets
    Composition:

    1 tablet, film-coated, contains:

    active substance:

    naphthyrofuryl oxalate 50 mg.

    Excipients:

    lactose monohydrate 47.50 mg, microcrystalline cellulose 63.50 mg,

    wheat starch 28.00 mg, sodium glycollate starch (type A) 4.80 mg, copovidone 10.00 mg,

    4.80 krosovnondon, silicon dioxide colloid 4,00 mg, magnesium stearate 7.20 mg, talc 10.20 mg.

    composition of film shell: titanium dioxide 1.04 mg, talc 1.99 mg, macrogol 6000 0.182 mg, methacrycatch acid and ethyl acrylate copolymer 0.68 mg, dibutyl phthalate 0.068 mg, dye sunset yellow E110.

    Description:

    Round biconvex tablets covered with a film coat, orange.

    Pharmacotherapeutic group:vasodilator
    ATX: & nbsp

    C.04.A.X.21   Naphthyrofuryl

    Pharmacodynamics:

    Naphthyrofuryl possesses vasodilator action, which improves peripheral and cerebral circulation. It causes a decrease in peripheral vascular resistance and increases the minute volume of the heart without significantly affecting the heart rate and blood pressure. The vasodilating effect of naphthydrofuril is the result of its selective action on 5HT2-receptors of platelets and the smooth muscle vascular layer.As a result of vasodilatation caused by the action of naphthydrofuril, there is an improvement in microcirculation in the peripheral tissues, the brain and the eye.

    Provides M-holinoblocking act. Under conditions of ischemia naphthydrofuryl causes a decrease in anaerobic metabolism, which leads to an increase concentrations and decrease of lactate-pyruvate coefficient. As a result, the resistance of cells (including the brain) to hypoxia increases. The drug improves cognitive function of the brain, reduces episodes of dizziness and headache, induces an improvement in sleep. Naphthyrofuryl improves the rheology of blood by inhibiting the aggregation of platelets and increasing the elastic properties of red blood cells.

    Pharmacokinetics:

    Naphthyrofuryl is almost completely absorbed when taken orally. Food has little effect on its absorption. After taking a single dose of 100 mg, the maximum plasma concentration is observed after 45-60 minutes and is 175 μg / ml. It is precluded by hepatic recirculation, which contributes to its longer residence in the plasma. Connection with blood proteins - 80%. Penetrates through blood-brain barrier.

    The maximum concentration in the brain tissue is observed after 60 minutes. After 24 hours after intake, its concentration in the brain tissues is 3 times higher than in plasma. There is no data on the penetration of paftidrofurple through the placenta and into breast milk. Metabolized mainly in the liver by hydrolysis, which is carried out by plasma esterases. The main metabolites studied are naphroleic acid and diethylaminoethanol, which has a stimulating effect on the central nervous system. The period of excretion is 1-2 hours with a single dose of 100 mg and 3.5 hours - with the intake of 200 mg.

    It is excreted from the body mainly through the intestine and in a small number by the kidneys. There is no evidence of a change in the rate of its excretion in cases of impaired liver or kidney function. Age does not affect the pharmacokinetic parameters of the drug.

    Indications:

    -Destruction cerebral blood circulation on background atherosclerotic lesions of cerebral vessels and cerebral vascular insufficiency, especially in the elderly.

    -Disruptions peripheral blood circulation: syndrome "intermittent" lameness, Raynaud's disease and syndrome, seizures gastrocnemius muscles, leg pain at rest, paresthesia, acrocyanosis. Trophic disorders (long non-healing ulcers, diabetic retinopathy).

    Contraindications:

    Increased individual sensitivity to the drug, myocardial infarction (acute stage); arterial hypotension; hemorrhagic stroke (acute stage); epilepsy, increased convulsive alertness; chronic heart failure II-III st. (III-IV by NYHA - functional classification of heart failure of the New York Heart Association); tachyarrhythmias.

    Age to 18 years (efficiency and safety are not installed.
    Carefully:closed-angle glaucoma, prostate hyperplasia.
    Pregnancy and lactation:

    Duzopharm does not have a teratogenic effect; special studies of its safety in pregnant women have not been conducted, it is recommended to prescribe the drug only in cases when the benefit of treatment for the mother exceeds the potential risk for the fetus.

    It is not recommended to take the drug during breastfeeding.

    Dosing and Administration:

    Inside. Tablets are taken entirely with the amount of liquid not less than a glass, it is recommended to drink it with water.

    Duzopharm is shown for long oral therapy. In case of violations cerebral blood circulation: recommendsulks Pryem drug in a daily dose of 300 mg to 600 mg, divided into three doses in a single dose of 100 mg.

    In cases of peripheral blood circulation: it is recommended to take the drug in a daily dose of 400 to 600 mg, in a single dose of 200 mg.

    Duration of therapy and dosing are determined by the doctor depending on the clinical condition of the patient. Correction of the dose in renal / hepatic insufficiency is not required.

    Side effects:

    When administered orally in doses of 300 before 600 mg Duzopharm is well tolerated as a whole. Nausea, vomiting, epigastric pain, intestinal colic, diarrhea, decreased appetite, headache, dizziness, sleep disturbances, reversible enhancing the activity of hepatic enzymes, ulcers of the gastric mucosa, allergic reactions.

    Overdose:

    Symptoms: increased severity of side effects, ventricular arrhythmia, anxiety, lowering of blood pressure, bradycardia.

    Treatment: gastric lavage, the appointment of activated carbon and laxatives, symptomatic treatment. There is no specific antidote.

    Interaction:

    Strengthens the antihypertensive effect of antihypertensive drugs. In this regard, more frequent control of blood pressure at the beginning of treatment with Duzopharm and antihypertensive agents is recommended at the same time.

    Special instructions:

    At the beginning of treatment it is recommended to monitor individual tolerance of the drug and trace possible hypotensive effect in the respective patients.

    The medicinal preparation contains lactose monohydrate, therefore it is unsuitable for persons suffering from lactose insufficiency, galactosemia or glucosogalactose malabsorption syndrome.

    Patients with celiac disease (gluten enteropathy) should take into account that the composition of the tablet includes wheathlt; / RTI & gt;

    Effect on the ability to drive transp. cf. and fur:Duzopharm does not adversely affect psychomotor reactions and the ability to drive a car.
    Form release / dosage:

    Tablets, film-coated 50 mg.

    10 tablets coated film shell in a blister of PVC / aluminum foil.

    By 3, 6 or 9 blisters together with instructions for use in a cardboard box.

    Storage conditions:

    In dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.

    Shelf life:

    3 years.

    Do not take after the expiry date printed on the package!

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002740/09
    Date of registration:07.04.2009
    The owner of the registration certificate:ESCO PHARMA, LLCESCO PHARMA, LLC
    Manufacturer: & nbsp
    Representation: & nbspESCO PHARMA, LLCESCO PHARMA, LLC
    Information update date: & nbsp31.07.2015
    Illustrated instructions
      Instructions
      Up